Immunosuppressive therapy in lupus- and mixed connective tissue disease-associated pulmonary arterial hypertension: a retrospective analysis of twenty-three cases.

OBJECTIVE To describe the response to first-line immunosuppressive therapy with or without pulmonary vasodilators in pulmonary arterial hypertension (PAH) associated with systemic lupus erythematosus (SLE) or mixed connective tissue disease (MCTD). METHODS Twenty-three consecutive patients with SLE- or MCTD-associated PAH treated with first-line immunosuppressive therapy either alone (n = 16) or in combination with pulmonary vasodilators (n = 7) were evaluated according to clinical and hemodynamic criteria before and after immunosuppressive therapy. Responders were defined as patients in New York Heart Association (NYHA) functional class I or II with hemodynamic improvement after the last pulse of cyclophosphamide. RESULTS Among the 16 patients treated with first-line immunosuppressive therapy alone, 8 (50%) were responders. These patients had a significantly improved NYHA functional class, 6-minute walking distance, and mean pulmonary artery pressure. Patients in NYHA functional class I or II and/or a cardiac index >3.1 liters/minute/m(2) at baseline were more likely to benefit from immunosuppressive therapy. Six of the 8 nonresponders subsequently improved with pulmonary vasodilators. Among the 7 patients who were initially treated with immunosuppressive therapy and pulmonary vasodilators, 4 (57.1%) were responders. CONCLUSION PAH associated with SLE or MCTD may respond to a treatment combining cyclophosphamide and glucocorticoids. Patients who could benefit from this immunosuppressive therapy could be those who have less severe disease at baseline. For patients with more severe disease, pulmonary vasodilators should be started, possibly in combination with immunosuppressants. In any case, clinical and hemodynamic evaluations are mandatory to monitor the response and adapt the treatment. These retrospective and uncontrolled data need to be confirmed by randomized controlled trials.

[1]  M. Humbert,et al.  Fibrous remodeling of the pulmonary venous system in pulmonary arterial hypertension associated with connective tissue diseases. , 2007, Human pathology.

[2]  M. Humbert,et al.  Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension. , 2006, Chest.

[3]  M. Humbert,et al.  Pulmonary arterial hypertension in France: results from a national registry. , 2006, American journal of respiratory and critical care medicine.

[4]  M. Humbert,et al.  Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. , 2006, European heart journal.

[5]  M. Humbert,et al.  Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. , 2005, Arthritis and rheumatism.

[6]  A. Branzi,et al.  Pulmonary arterial hypertension associated to connective tissue diseases , 2005, Lupus.

[7]  M. Humbert,et al.  Long-Term Response to Calcium Channel Blockers in Idiopathic Pulmonary Arterial Hypertension , 2005, Circulation.

[8]  G. Contreras,et al.  Maintenance Therapies for Proliferative Lupus Nephritis: Mycophenolate Mofetil, Azathioprine and Intravenous Cyclophosphamide , 2005 .

[9]  M. Humbert,et al.  Treatment of pulmonary arterial hypertension. , 2004, The New England journal of medicine.

[10]  M. Humbert,et al.  Cellular and molecular pathobiology of pulmonary arterial hypertension. , 2004, Journal of the American College of Cardiology.

[11]  M. Humbert,et al.  Inflammation in pulmonary arterial hypertension , 2003, European Respiratory Journal.

[12]  L. Tanoue.  Pulmonary Hypertension in the Collagen Vascular Diseases , 2003, Seminars in respiratory and critical care medicine.

[13]  L. Mouthon,et al.  Treatment of polyarteritis nodosa and microscopic polyangiitis with poor prognosis factors: a prospective trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in sixty-five patients. , 2003, Arthritis and rheumatism.

[14]  M. Humbert,et al.  CX3C Chemokine Fractalkine in Pulmonary Arterial Hypertension , 2002 .

[15]  D. Gladman,et al.  Systemic lupus erythematosus disease activity index 2000. , 2002, The Journal of rheumatology.

[16]  N. Kamatani,et al.  Pulmonary hypertension in systemic lupus erythematosus: evaluation of clinical characteristics and response to immunosuppressive treatment. , 2002, The Journal of rheumatology.

[17]  A. Takeshita,et al.  Severe pulmonary hypertension in a patient with systemic lupus erythematosus and minimal lupus activity. , 2002, Internal medicine.

[18]  R. Speich,et al.  Clinical classification of pulmonary hypertension. , 2004, Journal of the American College of Cardiology.

[19]  R. Wise,et al.  Cyclophosphamide Is Associated with Pulmonary Function and Survival Benefit in Patients with Scleroderma and Alveolitis , 2000, Annals of Internal Medicine.

[20]  J. Loyd,et al.  Epoprostenol for treatment of pulmonary hypertension in patients with systemic lupus erythematosus. , 2000, Chest.

[21]  M. Humbert,et al.  Treatment of pulmonary hypertension secondary to connective tissue diseases , 1999, Thorax.

[22]  M. Harigai,et al.  Corticosteroid pulse therapy in a patient with SLE and pulmonary hypertension. , 1998, Clinical and experimental rheumatology.

[23]  M. Humbert,et al.  Platelet-derived growth factor expression in primary pulmonary hypertension: comparison of HIV seropositive and HIV seronegative patients. , 1998, The European respiratory journal.

[24]  M. Hochberg,et al.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. , 1997, Arthritis and rheumatism.

[25]  G. Simonneau,et al.  Improvement of severe pulmonary hypertension in a patient with SLE. , 1996, Annals of the rheumatic diseases.

[26]  N. Minato,et al.  Pulmonary hypertension in systemic lupus erythematosus: a report of an autopsied case. , 1994, Internal medicine.

[27]  B. Groves,et al.  Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. , 1994, The American journal of pathology.

[28]  D. Postma,et al.  Primary pulmonary hypertension in a patient with systemic lupus erythematosus: partial improvement with cyclophosphamide. , 1993, The Journal of rheumatology.

[29]  G. Hughes,et al.  Pulmonary hypertension in a lupus clinic: experience with twenty-four patients. , 1990, The Journal of rheumatology.

[30]  D. Alarcón-Segovia,et al.  Comparison between 3 diagnostic criteria for mixed connective tissue disease. Study of 593 patients. , 1989, The Journal of rheumatology.

[31]  W. Mccune,et al.  Clinical and immunologic effects of monthly administration of intravenous cyclophosphamide in severe systemic lupus erythematosus. , 1988, The New England journal of medicine.

[32]  H. Perez,et al.  Pulmonary hypertension in systemic lupus erythematosus: report of four cases and review of the literature. , 1981, Seminars in arthritis and rheumatism.

[33]  J. Brentjens,et al.  Disseminated immune deposits in lupus erythematosus. , 1977, Arthritis and rheumatism.

[34]  P. Yeo,et al.  Lupus cor pulmonale with electron microscope and immunofluroescent antibody studies. , 1975, Annals of the rheumatic diseases.